{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Chaoyang C"],"pubmed_abstract":["<b>Objectives:</b> This study aimed to investigate the pharmacokinetic characteristics of siponimod in healthy volunteers and patients with MS based on aggregated data from published clinical trials, and to explore the factors influencing siponimod exposure. <b>Methods:</b> A total of 476 siponimod plasma concentrations aggregated from 28 dosage groups (corresponding to 294 healthy volunteers and 207 patients with MS) were collected from published clinical trials. Population pharmacokinetic (PPK) analysis was performed using a nonlinear, mixed-effect modeling approach. The pharmacokinetic properties of siponimod in healthy volunteers and patients with MS were compared, and the influence of covariates on siponimod exposure was evaluated using both PPK analysis and noncompartmental analysis "],"journal":["Frontiers in pharmacology"],"pagination":["824232"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9127076"],"repository":["biostudies-literature"],"pubmed_title":["Pharmacokinetic Characteristics of Siponimod in Healthy Volunteers and Patients With Multiple Sclerosis: Analyses of Published Clinical Trials."],"pmcid":["PMC9127076"],"pubmed_authors":["Xiu D","Enyao Z","Lingyun M","Zhenming L","Chaoyang C","Ran W","Ruoming L","Ying Z","Yimin C","Simiao Z"],"additional_accession":[]},"is_claimable":false,"name":"Pharmacokinetic Characteristics of Siponimod in Healthy Volunteers and Patients With Multiple Sclerosis: Analyses of Published Clinical Trials.","description":"<b>Objectives:</b> This study aimed to investigate the pharmacokinetic characteristics of siponimod in healthy volunteers and patients with MS based on aggregated data from published clinical trials, and to explore the factors influencing siponimod exposure. <b>Methods:</b> A total of 476 siponimod plasma concentrations aggregated from 28 dosage groups (corresponding to 294 healthy volunteers and 207 patients with MS) were collected from published clinical trials. Population pharmacokinetic (PPK) analysis was performed using a nonlinear, mixed-effect modeling approach. The pharmacokinetic properties of siponimod in healthy volunteers and patients with MS were compared, and the influence of covariates on siponimod exposure was evaluated using both PPK analysis and noncompartmental analysis ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-04T18:53:38.618Z","creation":"2025-04-04T18:53:38.618Z"},"accession":"S-EPMC9127076","cross_references":{"pubmed":["35620290"],"doi":["10.3389/fphar.2022.824232"]}}